The Latest News and Updates in Mantle Cell Lymphoma

There have been several updates in the field of mantle cell lymphoma over the last several weeks. Here, CURE® looks back at some of the latest news and updates affecting patients with that cancer type.

• Data from an analysis of approximately 1,200 patients with mantle cell lymphoma (MCL) collected across 12 treatment centers presented at the 2020 ASCO Virtual Scientific Program demonstrated that maintenance Rituxan (rituximab) was associated with improved progression-free survival and overall survival, but an autologous stem cell transplant was not.
• Understanding the genetic mutational profile of patients with MCL can be a useful risk-stratification tool in helping to best identify appropriate treatment options, according to Dr. Jia Ruan.
• The Food and Drug Administration’s (FDA) recent approval of Tecartus (brexucabtagene autoleucel, formerly KTE-X19) for the treatment of adults with relapsed or refractory MCL will forever change the way the disease is treated, according to Dr. Michael Wang.
• “It really is an exciting time for patients with lymphoma, because the options are just really exploding at a very encouraging rate,” said Dr. Lori A. Leslie in a recent interview.
• “We now have second and third generation cousins of thalidomide that are very useful. So, lenalidomide in combination with rituximab is an effective therapy for mantle cell lymphoma that voids some of these adverse events that I’m talking about,” said Dr. Ian Flinn in a recent interview with CURE®.